Cost effectiveness of endometrial ablation with the NovaSure® system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and medicaid payer perspectives

International Journal of Women's Health

Volumn 7, Issue , 2015, Pages 59-73

  Miller, Jeffrey D ^a   Lenhart, Gregory M ^a   Bonafede, Machaon M ^a   Basinski, Cindy M ^b   Lukes, Andrea S ^c   Troeger, Kathleen A ^d  

^a IBM WATSON HEALTH   (United States)

^b Basinski LLC   (United States)

^c Carolina Women's Research and Wellness Center   (United States)

^d HOLOGIC INC   (United States)

Author keywords

Abnormal uterine bleeding; Cost effectiveness analysis; Global endome trial ablation; Hysterectomy; Menorrhagia; NovaSure

Indexed keywords

TRANEXAMIC ACID;

ABSENTEEISM; ADULT; ARTICLE; CERVICAL OCCLUSION; CERVICAL SPINE INJURY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY; ENDOMETRIUM ABLATION; FEMALE; GYNECOLOGIC THERMAL ABLATION DEVICE; HEALTH CARE COST; HEMATOMETRA; HUMAN; HYPERVOLEMIA; HYSTERECTOMY; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; PREGNANCY; PYOMETRA; QUALITY ADJUSTED LIFE YEAR; RADIOFREQUENCY ABLATION DEVICE; TREATMENT OUTCOME; UTERINE CERVICITIS; UTERINE CERVIX DISEASE; UTERUS BLEEDING; UTERUS PERFORATION;

EID: 84920913627     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S75030     Document Type: Article

References (54)

1. American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins – Gynecology. Practice bulletin no 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013;122(1):176–185.
2. American Congress of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins – Gynecology. Practice bulletin no 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012;120(1):197–206.
3. Fox KE. Management of heavy menstrual bleeding in general practice. Curr Med Res Opin. 2012;28(9):1517–1525.
4. Munro MG, Critchley HO, Fraser IS. The FIGO classification of causes of abnormal uterine bleeding: Malcolm G Munro, Hilary OD Crithcley, Ian S Fraser, for the FIGO Working Group on Menstrual Disorders. Int J Gynaecol Obstet. 2011;113(1):3–13.
5. UK National Institute for Clinical Excellence (NICE). Heavy Menstrual Bleeding: Clinical Guideline 44; 2007. Available from: http://www.nice.org.uk/nicemedia/pdf/CG44FullGuideline.pdf. Accessed October 18, 2014.
6. Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve inter­national agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007;22(3):635–643.
7. Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A. Treatment of menorrhagia. Am Fam Physician. 2007;75(12):1813–1819.
8. Osei J, Critchley H. Menorrhagia, mechanisms and targeted therapies. Curr Opin Obstet Gynecol. 2005;17(4):411–418.
9. Oehler MK, Rees MC. Menorrhagia: an update. Acta Obstet Gynecol Scand. 2003;82(5):405–422.
10. Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP. Evaluation and management of abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2012;85(1):35–43.
11. Centers for Disease Control and Prevention (CDC). Blood Disorders in Women: Heavy Menstrual Bleeding; 2011. Available from: http://www.cdc.gov/ncbddd/blooddisorders/women/menorrhagia.html. Accessed October 18, 2014.
12. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183–194.
13. Spencer CP, Whitehead MI. Endometrial assessment re-visited. Br J Obstet Gynaecol. 1999;106(7):623–632.
14. Stovall DW. Alternatives to hysterectomy: focus on global endometrial ablation, uterine fibroid embolization, and magnetic resonance-guided focused ultrasound. Menopause. 2011;18(4):437–444.
15. Canali C. Global endometrial ablation for menorrhagia: the office option. OBG Manage. 2012;Suppl:S1–S8.Available from: http://www.obgmanagement.com/uploads/media/SupplOBG_Omnia1.pdf. Accessed October 18, 2014.
16. US Food and Drug Administration (FDA). NovaSure™ Impedance Controlled Endometrial Ablation System – P010013; 2001. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf/P010013a.pdf. Accessed October 18, 2014.
17. Gimpelson RJ. Ten-year literature review of global endometrial ablation with the NovaSure® device. Int J Womens Health. 2014;6:269–280.
18. Cooper J, Gimpelson R, Laberge P, et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002;9(4):418–428.
19. Cooper J, Gimpelson RJ. Summary of safety and effectiveness data from FDA: a valuable source of information on the performance of global endometrial ablation devices. J Reprod Med. 2004;49(4):267–273.
20. Clark TJ, Samuel N, Malick S, Middleton LJ, Daniels J, Gupta JK. Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial. Obstet Gynecol. 2011;117(1):109–118.
21. Penninx JP, Mol BW, Engels R, et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):819–826.
22. El-Nashar SA, Hopkins MR, Creedon DJ, et al. Prediction of treat­ment outcomes after global endometrial ablation. Obstet Gynecol. 2009;113(1):97–106.[Erratum in: Obstet Gynecol. Mar 2010; 115(3):663].
23. Gallinat A. An impedance-controlled system for endometrial abla­tion: five-year follow-up of 107 patients. J Reprod Med. 2007;52(6): 467–472.
24. Fulop T, Rákóczi I, Barna I. NovaSure impedance controlled endome­trial ablation: long-term follow-up results. J Minim Invasive Gynecol. 2007;14(1):85–90.
25. Kleijn JH, Engels R, Bourdrez P, Mol BW, Bongers MY. Five-year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. BJOG. 2008;115(2):193–198.
26. Bongers MY. Second-generation endometrial ablation treatment: Novasure. Best Pract Res Clin Obstet Gynaecol. 2007;21(6): 989–994.
27. Laberge PY. NovaSure(): the bipolar radiofrequency endometrial ablation system for dysfunctional uterine bleeding. Womens Health (Lond Engl). 2006;2(5):687–693.
28. Abbott J, Hawe J, Hunter D, Garry R. A double-blind randomized trial comparing the Cavaterm and the NovaSure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertil Steril. 2003;80(1):203–208.
29. American College of Obstetricians and Gynecologists. ACOG committee opinion no 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891–896.
30. Bonafede MM, Miller JD, Meyer NM, Lenhart GM. Comparative direct and indirect costs of menorrhagia treatment with global endometrial ablation or hysterectomy. Poster (#PIH17) presented at: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting, May 18–22; 2013; New Orleans, LA.
31. Bonafede MM, Miller JD, Meyer NM, Lenhart GM. Retrospective database analysis of clinical outcomes and costs for treatment of menorrhagia among women enrolled in US Medicaid programs. Poster (#PIH22) presented at: The International Society for Pharmacoeconom­ics and Outcomes Research (ISPOR) 18th Annual International Meeting, May 18–22; 2013; New Orleans, LA.
32. Bhattacharya S, Middleton LJ, Tsourapas A, et al; International Heavy Menstrual Bleeding Individual Patient Data Meta-analysis Collaborative Group. Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis. Health Technol Assess. 2011;15(19):iii–xvi. , 1–252.
33. Roberts TE, Tsourapas A, Middleton LJ, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ. 2011;342:d2202.
34. Clegg JP, Guest JF, Hurskainen R. Cost-utility of levonorgestrel intrauterine system compared with hysterectomy and second generation endometrial ablative techniques in managing patients with menorrhagia in the UK. Curr Med Res Opin. 2007;23(7):1637–1648.
35. Garside R, Stein K, Wyatt K, Round A, Price A. The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling. Health Technol Assess. 2004;8(3): 1–155.
36. Garside R, Stein K, Wyatt K, Round A, Pitt M. A cost-utility analysis of microwave and thermal balloon endometrial ablation techniques for the treatment of heavy menstrual bleeding. BJOG. 2004;111(10): 1103–1114.
37. Bonafede MM, Miller JD, Laughlin-Tommaso SK, Lukes AS, Meyer NM, Lenhart GM. Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs. Clinicoecon Outcomes Res. 2014;6:423–429.
38. Baskett TF, Clough H, Scott TA. NovaSure bipolar radiofrequency endometrial ablation: report of 200 cases. J Obstet Gynaecol Can. 2005;27(5):473–476.
39. Busund B, Erno LE, Grønmark A, Istre O. Endometrial ablation with NovaSure GEA, a pilot study. Acta Obstet Gynecol Scand. 2003;82(1): 65–68.
40. Campbell P, Monaghan C, Parker M. NovaSure endometrial ablation: a review of 400 cases. Gynecol Surg. 2012;9:73–76.
41. Claas MJ, Wirjosoekarto SAM, Bukman A, Lenters E. NovaSure® endometrial ablation: effectiveness and patient satisfaction. J Gynecol Surg. 2012;28(2):89–93.
42. Elmardi A, Furara S, Khan F, Hamza M. NovaSure impedance con­trolled system for endometrial ablation: the experience of the first UK reference centre. J Obstet Gynaecol. 2009;29(5):419–422.
43. El-Nashar SA, Hopkins MR, Creedon DJ, Cliby WA, Famuyide AO. Efficacy of bipolar radiofrequency endometrial ablation vs thermal balloon ablation for management of menorrhagia: a population-based cohort. J Minim Invasive Gynecol. 2009;16(6):692–699.
44. Ghazizadeh S, Panahi Z, Ghanbari Z, Menshadi AT, Farahmandian T, Javadian P. Comparative efficacy of NovaSure, the levonorgestrel-releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: randomized clinical trial. J Gynecol Surg. 2014;30(4):215–218.
45. Kalkat RK, Cartmill RS. NovaSure endometrial ablation under local anaesthesia in an outpatient setting: an observational study. J Obstet Gynaecol. 2011;31(2):152–155.
46. Jensen JT, Lefebvre P, Laliberté F, et al. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt). 2012;21(5):539–547.
47. Pron G, Cohen M, Soucie J, et al; Ontario Uterine Fibroid Embolization Collaboration Group. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril. 2003;79(1):112–119.
48. Côté I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol. 2002;100(4): 683–687.
49. Hurskainen R, Aalto AM, Teperi J, et al. Psychosocial and other char­acteristics of women complaining of menorrhagia, with and without actual increased menstrual blood loss. BJOG. 2001;108(3):281–285.
50. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Womens Health (Larchmt). 2013;22(4):378–384.
51. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Womens Health. 2012;4:271–278.
52. Sculpher M. A cost-utility analysis of abdominal hysterectomy ver­sus transcervical endometrial resection for the surgical treatment of menorrhagia. Int J Technol Assess Health Care. 1998;14(Spring 2):302–319.
53. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004;291(12):1456–1463.
54. Maresh MJ, Metcalfe MA, McPherson K, et al. The VALUE national hysterectomy study: description of the patients and their surgery. BJOG. 2002;109(3):302–312.